<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="t1" orientation="portrait" position="float">
 <label>TABLE I</label>
 <caption>
  <title>
   <italic>In silico</italic> studies of drug repurposing for coronavirus disease 2019 (COVID-19)
  </title>
 </caption>
 <table frame="hsides" rules="groups">
  <colgroup span="1">
   <col span="1"/>
   <col span="1"/>
   <col span="1"/>
   <col span="1"/>
   <col span="1"/>
   <col span="1"/>
  </colgroup>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">Repurposed drug</td>
    <td align="center" rowspan="1" colspan="1">Previous use</td>
    <td align="center" rowspan="1" colspan="1">Predicted targets</td>
    <td align="center" rowspan="1" colspan="1">Discovery origin</td>
    <td align="center" rowspan="1" colspan="1">Experimental evidence</td>
    <td align="center" rowspan="1" colspan="1">Reference</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Pemirolast (30), nitrofurantoin (31), isoniazid pyruvate (32), eriodictyol (33), cepharanthine (34), ergoloid (35) and hypericin (36)</td>
    <td align="center" rowspan="1" colspan="1">Multiple</td>
    <td align="center" rowspan="1" colspan="1">Disrupting spike protein (S-protein) and ACE2 receptor interaction or inhibit S-protein and block ACE2 receptor</td>
    <td align="center" rowspan="1" colspan="1">Ensemble docking</td>
    <td align="center" rowspan="1" colspan="1">Natural products, such as eriodictyol (33), cepharanthin (34), ergoloid (35) and hypericin (36) have shown antiviral activity against coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV).
     <sup>
      <italic>a</italic>
     </sup>
    </td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B160" ref-type="bibr">
      <sup>160</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Mefuparib hydrochloride (CVL218) (37)</td>
    <td align="center" rowspan="1" colspan="1">Cancer</td>
    <td align="center" rowspan="1" colspan="1">Nucleocapsid (N protein)</td>
    <td align="center" rowspan="1" colspan="1">Knowledge-graph docking 
     <italic>in vitro</italic> and 
     <italic>in vivo</italic> assays
    </td>
    <td align="center" rowspan="1" colspan="1">Mefuparib (37) achieved an EC
     <sub>50</sub> of 5.12 Î¼M.
    </td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B164" ref-type="bibr">
      <sup>164</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Atazanavir (12) and efavirenz (38)</td>
    <td align="center" rowspan="1" colspan="1">HIV</td>
    <td align="center" rowspan="1" colspan="1">SARS-CoV-2 3C-like protease (M
     <sup>pro</sup>)
    </td>
    <td align="center" rowspan="1" colspan="1">Molecule transformer drug-target interaction (MT-DTI)</td>
    <td align="center" rowspan="1" colspan="1">Atazanavir (12) can been found in lungs after administration and have shown inhibitory activity against M
     <sup>pro</sup>.
     <sup>
      <italic>b</italic>
     </sup>
    </td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B103" ref-type="bibr">
      <sup>103</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Baricitinib (39)</td>
    <td align="center" rowspan="1" colspan="1">Rheumatoid arthritis</td>
    <td align="center" rowspan="1" colspan="1">Human AP2-associated protein kinase 1 (AAK1)</td>
    <td align="center" rowspan="1" colspan="1">Knowledge-graph</td>
    <td align="center" rowspan="1" colspan="1">A pilot trial indicated that baricitinib (39) improved clinical parameters (e.g., cough and dyspnea) in a small group of patients.
     <sup>
      <italic>c</italic>
     </sup>
    </td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B161" ref-type="bibr">
      <sup>161</sup>
     </xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Toremifene (40), sirolimus (41), mercaptopurine (42), irbesartan (43)</td>
    <td align="center" rowspan="1" colspan="1">Multiple</td>
    <td align="center" rowspan="1" colspan="1">Multiple targets in humans and coronaviruses</td>
    <td align="center" rowspan="1" colspan="1">Systems pharmacology-based network and human protein-protein (PPI) network</td>
    <td align="center" rowspan="1" colspan="1">Antiviral activities against coronaviruses has been described for selective estrogen modulators toremifene (40), immunosuppressants sirolimus (41) and mercaptopurine (42) and angiotensin receptor blockers irbesartan (43).
     <sup>
      <italic>d</italic>
     </sup>
    </td>
    <td align="center" rowspan="1" colspan="1">
     <xref rid="B52" ref-type="bibr">
      <sup>52</sup>
     </xref>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="TFN1">
   <p>
    <italic>a</italic>: Cepharanthin (34) has been shown to decrease the expression levels of S-protein in MRC-5 cells infected with 
    <italic>Human coronavirus OC43</italic> (
    <italic>HCoV</italic>-
    <italic>OC43</italic>).
    <xref rid="B165" ref-type="bibr">
     <sup>165</sup>
    </xref> Flavonoids have been described as inhibitors of M
    <sup>pro</sup> and ligands of the S-protein of SARS-CoV, which could give insights on possible antiviral activities of eriodictyol (33), hypericin (36) and other flavonoids on SARS-CoV-2.
    <xref rid="B166" ref-type="bibr">
     <sup>166</sup>
    </xref>
    <sup>,</sup>
    <xref rid="B167" ref-type="bibr">
     <sup>167</sup>
    </xref>
    <italic>b</italic>: a recent study showed that Atazanavir (12) inhibited M
    <sup>pro</sup>
    <italic>in vitro</italic> with greater potency than lopinavir (1).
    <xref rid="B168" ref-type="bibr">
     <sup>168</sup>
    </xref>
    <italic>c</italic>: despite the small size (12 patients) and open label, non-randomised format, baricitinib (39) showed potential safety when used in combination with lopinavir (1) / ritonavir (2).
    <xref rid="B169" ref-type="bibr">
     <sup>169</sup>
    </xref> As of August 3rd 13th, 2020, there are three ongoing clinical trials with baricitinib (39): NCT04421027 (phase 2, randomised and double blind), NCT04320277 (phases 2 and 3, non-randomised and open-label) and NCT04321993 (phase 2, non-randomised and open-label). 
    <italic>d</italic>: the authors described previous antiviral activities for the most promising drugs, including against other coronaviruses (e. g., MERS-CoV and SARS-CoV), showing a correlation between the original target of each drug and coronaviruses target.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
